Recombinant adeno-associated viruses (AAVs) are quickly becoming the preferred viral vector for viral gene delivery for the treatment of a wide variety of genetic disorders. However, since their use in a clinical trial targeting hemophilia B patients 10 years ago, immune responses to the AAV capsid appear to have hampered some of the early clinical gene transfer efficacy. Indeed, AAV-based gene transfer has been shown to reactivate capsid-specific memory T cells, which have correlated with a decline in AAV-transduced tissue in some patients. Importantly, clinical trials have also shown that this reactivation can be quelled by administering time-course taper of glucocorticoid steroids before or after dosing. More recently, two clinical studies have shown that AAV gene transfer is not only able to induce a deleterious immune response, but also can result in the initiation of a tolerance to the AAV capsid mediated by regulatory T cells and exhausted T cells. This article reviews clinical trials describing immune responses to AAV, as well as the mechanisms responsible for immune tolerance in chronic infections and how it could apply to AAV-based gene transfer. A better understanding of both cytotoxic and tolerogenic immune responses to recombinant AAV will lead to safer gene transfer protocols in patients.
Get full access to this article
View all access options for this article.
References
1.
JoossK, YangY, FisherKJ, et al.Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol, 1998; 72:4212–4223.
2.
MannoCS, PierceGF, ArrudaVR, et al.Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat Med, 2006; 12:342–347.
3.
MingozziF, MausMV, HuiDJ, et al.CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med, 2007; 13:419–422.
4.
SnyderRO, MiaoC, MeuseL, et al.Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med, 1999; 5:64–70.
5.
MountJD, HerzogRW, TillsonDM, et al.Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood, 2002; 99:2670–2676.
6.
NathwaniAC, TuddenhamEGD, RangarajanS, et al.Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med, 2011; 365:2357–2365.
7.
Spark Therapeutics. Spark Therapeutics and Pfizer present updated preliminary data from hemophilia B phase 1/2 trial suggesting consistent and sustained levels of factor IX activity at annual ASH meeting. Press release: http://ir.sparktx.com/phoenix.zhtml?c=253900&p=irol-newsArticle&ID=2227316 (last accessed December2016).
8.
UniQure. Second-dose cohort demonstrates dose response with all patients free of prophylactic FIX replacement therapy and only one spontaneous bleed reported. Press release: https://tools.eurolandir.com/tools/Pressreleases/GetPressRelease/?ID=3302307&lang=en-GB&companycode=nl-qure&v= (last accessed December2016).
FerreiraV, TwiskJ, KwikkersK, et al.Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPL(S447X)) in a Phase II clinical trial of lipoprotein lipase deficiency gene therapy. Hum Gene Ther, 2014; 25:180–188.
11.
SakaguchiS, SakaguchiN, AsanoM, et al.Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol, 1995; 155:1151–1164.
12.
BluestoneJA, AbbasAK. Natural versus adaptive regulatory T cells. Nat Rev Immunol, 2003; 3:253–257.
13.
Flores-BorjaF, JuryEC, MauriC, et al.Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proc Natl Acad Sci U S A, 2008; 105:19396–19401.
14.
ZhengY, ManzottiCN, BurkeF, et al.Acquisition of suppressive function by activated human CD4+ CD25- T cells is associated with the expression of CTLA-4 not FoxP3. J Immunol, 2008; 181:1683–1691.
15.
Baecher-AllanC, WolfE, HaflerDA. MHC class II expression identifies functionally distinct human regulatory T cells. J Immunol, 2006; 176:4622–4631.
16.
BorsellinoG, KleinewietfeldM, Di MitriD, et al.Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood, 2007; 110:1225–1232.
17.
LiuW, PutnamAL, Xu-YuZ, et al.CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med, 2006; 203:1701–1711.
18.
HoriS, NomuraT, SakaguchiS. Control of regulatory T cell development by the transcription factor Foxp3. Science, 2003; 299:1057–1061.
19.
FontenotJD, GavinMA, RudenskyAY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol, 2003; 4:330–336.
20.
KhattriR, CoxT, YasaykoS-A, et al.An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol, 2003; 4:337–342.
21.
ThorntonAM, KilaruG, BurrP, et al.Helios expression defines two distinct populations of Foxp3+ regulatory T cells. J Immunol, 2016; 196:125.6.
22.
SebastianM, Lopez-OcasioM, MetidjiA, et al.Helios controls a limited subset of regulatory T cell functions. J Immunol, 2016; 196:144–155.
23.
PiccirilloCA, ShevachEM. Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol, 2001; 167:1137–1140.
24.
GrossmanWJ, VerbskyJW, BarchetW, et al.Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity, 2004; 21:589–601.
25.
CaoX, CaiSF, FehnigerTA, et al.Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity, 2007; 27:635–646.
26.
LoebbermannJ, ThorntonH, DurantL, et al.Regulatory T cells expressing granzyme B play a critical role in controlling lung inflammation during acute viral infection. Mucosal Immunol, 2012; 5:161–172.
27.
CederbomL, HallH, IvarsF. CD4+CD25+ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. Eur J Immunol, 2000; 30:1538–1543.
28.
MisraN, BayryJ, Lacroix-DesmazesS, et al.Cutting edge: human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol, 2004; 172:4676–4680.
29.
OnishiY, FehervariZ, YamaguchiT, et al.Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci U S A, 2008; 105:10113–10118.
30.
TadokoroCE, ShakharG, ShenS, et al.Regulatory T cells inhibit stable contacts between CD4+ T cells and dendritic cells in vivo. J Exp Med, 2006; 203:505–511.
31.
TangQ, AdamsJY, TooleyAJ, et al.Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol, 2006; 7:83–92.
32.
GrouxH, O'GarraA, BiglerM, et al.A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature, 1997; 389:737–742.
33.
ChenW, JinW, HardegenN, et al.Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med, 2003; 198:1875–1886.
34.
CollisonLW, ChaturvediV, HendersonAL, et al.IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol, 2010; 11:1093–1101.
35.
WeissL, Donkova-PetriniV, CaccavelliL, et al.Human immunodeficiency virus-driven expansion of CD4+CD25+ regulatory T cells, which suppress HIV-specific CD4 T-cell responses in HIV-infected patients. Blood, 2004; 104:3249–3256.
36.
XuD, FuJ, JinL, et al.Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol, 2006; 177:739–747.
37.
van der BurgSH, PiersmaSJ, de JongA, et al.Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. Proc Natl Acad Sci U S A, 2007; 104:12087–12092.
38.
CabreraR, TuZ, XuY, et al.An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. Hepatology, 2004; 40:1062–1071.
39.
LechnerF, WongDKH, DunbarPR, et al.Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med, 2000; 191:1499–1512.
40.
ZajacAJ, BlattmanJN, Murali-KrishnaK, et al.Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med, 1998; 188:2205–2213.
41.
WherryEJ. T cell exhaustion. Nat Immunol, 2011; 12:492–499.
42.
BlackburnSD, ShinH, HainingWN, et al.Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol, 2009; 10:29–37.
43.
VelazquezVM, BowenDG, WalkerCM. Silencing of T lymphocytes by antigen-driven programmed death in recombinant adeno-associated virus vector-mediated gene therapy. Blood, 2009; 113:538–545.
44.
LinJ, ZhiY, MaysL, et al.Vaccines based on novel adeno-associated virus vectors elicit aberrant CD8+ T-cell responses in mice. J Virol, 2007; 81:11840–11849.
45.
LinS-W, HensleySE, TatsisN, et al.Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice. J Clin Invest, 2007; 117:3958–3970.
46.
FlotteTR, TrapnellBC, HumphriesM, et al.Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing α1-antitrypsin: interim results. Hum Gene Ther, 2011; 22:1239–1247.
47.
MuellerC, GernouxG, GruntmanAM, et al.5 Year expression and neutrophil defect repair after gene therapy in alpha-1 antitrypsin deficiency. Mol Ther, 2017; [Epub ahead of print] DOI: 10.1016/j.ymthe.2017.03.029
48.
StroesES, NiermanMC, MeulenbergJJ, et al.Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler Thromb Vasc Biol, 2008; 28:2303–2304.
49.
MingozziF, MeulenbergJJ, HuiDJ, et al.AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood, 2009; 114:2077–2086.
50.
WangZ, KuhrCS, AllenJM, et al.Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol Ther, 2007; 15:1160–1166.
51.
WangZ, StorbR, HalbertCL, et al.Successful regional delivery and long-term expression of a dystrophin gene in canine muscular dystrophy: a preclinical model for human therapies. Mol Ther, 2012; 20:1501–1507.
52.
MingozziF, HasbrouckNC, Basner-TschakarjanE, et al.Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood, 2007; 110:2334–2341.
53.
NathwaniAC, ReissUM, TuddenhamEGD, et al.Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med, 2014; 371:1994–2004.
54.
FlaniganKM, CampbellK, ViolletL, et al.Anti-dystrophin T cell responses in Duchenne muscular dystrophy: prevalence and a glucocorticoid treatment effect. Hum Gene Ther, 2013; 24:797–806.
55.
MendellJR, Rodino-KlapacLR, Rosales-QuinteroX, et al.Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins. Ann Neurol, 2009; 66:290–297.
56.
MendellJR, CampbellK, Rodino-KlapacL, et al.Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med, 2010; 363:1429–1437.
57.
MendellJR, Al-ZaidyS, ShellR, et al.480. Gene therapy for spinal muscular atrophy type 1 shows potential to improve survival and motor functional outcomes. Mol Ther, 2016; 24:S190.
58.
ZhuJ, HuangX, YangY. The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice. J Clin Invest, 2009; 119:2388–2398.
59.
AldrichWA, RenC, WhiteAF, et al.Enhanced transduction of mouse bone marrow-derived dendritic cells by repetitive infection with self-complementary adeno-associated virus 6 combined with immunostimulatory ligands. Gene Ther, 2006; 13:29–39.
60.
VeronP, AlloV, RiviereC, et al.Major subsets of human dendritic cells are efficiently transduced by self-complementary adeno-associated virus vectors 1 and 2. J Virol, 2007; 81:5385–5394.
61.
VeronP, BoutinS, MartinS, et al.Highly efficient transduction of human plasmacytoid dendritic cells without phenotypic and functional maturation. J Transl Med, 2009; 7:10.
62.
GernouxG, GuilbaudM, DubreilL, et al.Early interaction of adeno-associated virus serotype 8 vector with the host immune system following intramuscular delivery results in weak but detectable lymphocyte and dendritic cell transduction. Hum Gene Ther, 2015; 26:1–13.
63.
BoutinS, MonteilhetV, VeronP, et al.Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther, 2010; 21:704–712.
64.
VeronP, LeborgneC, MonteilhetV, et al.Humoral and cellular capsid-specific immune responses to adeno-associated virus type 1 in randomized healthy donors. J Immunol, 2012; 188:6418–6424.
65.
MaysLE, WangL, LinJ, et al.AAV8 induces tolerance in murine muscle as a result of poor APC transduction, T cell exhaustion, and minimal MHCI upregulation on target cells. Mol Ther, 2014; 22:28–41.
66.
PandyaJ, OrtizL, LingC, et al.Rationally designed capsid and transgene cassette of AAV6 vectors for dendritic cell-based cancer immunotherapy. Immunol Cell Biol, 2014; 92:116–123.
67.
PandyaM, BrittK, HoffmanB, et al.Reprogramming immune response with capsid-optimized AAV6 vectors for immunotherapy of cancer. J Immunother, 2015; 38:292–298.
68.
LiH, TuyishimeS, WuT-L, et al.Adeno-associated virus vectors serotype 2 induce prolonged proliferation of capsid-specific CD8+ T cells in mice. Mol Ther, 2011; 19:536–546.
69.
StiegerK, SchroederJ, ProvostN, et al.Detection of intact rAAV particles up to 6 years after successful gene transfer in the retina of dogs and primates. Mol Ther, 2009; 17:516–523.
70.
OzeriE, MizrahiM, ShahafG, et al.α-1 antitrypsin promotes semimature, IL-10-producing and readily migrating tolerogenic dendritic cells. J Immunol, 2012; 189:146–153.
71.
WhartenbyKA, CalabresiPA, McCaddenE, et al.Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease. Proc Natl Acad Sci U S A, 2005; 102:16741–16746.
72.
RodionovaE, ConzelmannM, MaraskovskyE, et al.GSK-3 mediates differentiation and activation of proinflammatory dendritic cells. Blood, 2007; 109:1584–1592.
73.
OderupC, LaJevicM, ButcherEC. Canonical and noncanonical Wnt proteins program dendritic cell responses for tolerance. J Immunol, 2013; 190:6126–6134.
74.
BattagliaM, StabiliniA, MigliavaccaB, et al.Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol, 2006; 177:8338–8347.
75.
Biomarin. BioMarin provides encouraging preliminary data on first 8 patients in hemophilia A gene therapy program. Press release: https://globenewswire.com/news-release/2016/04/20/830721/0/en/BioMarin-Provides-Encouraging-Preliminary-Data-on-First-8-Patients-in-Hemophilia-A-Gene-Therapy-Program.html (last accessed December2016).
76.
GaudetD, MéthotJ, DéryS, et al.Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther, 2013; 20:361–369.
77.
McPheeSWJ, JansonCG, LiC, et al.Immune responses to AAV in a Phase I study for Canavan disease. J Gene Med, 2006; 8:577–588.
78.
TardieuM, ZérahM, HussonB, et al.Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a Phase I/II trial. Hum Gene Ther, 2014; 25:506–516.
79.
SimonelliF, MaguireAM, TestaF, et al.Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther, 2010; 18:643–650.
80.
BrantlyML, SpencerLT, HumphriesM, et al.Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults. Hum Gene Ther, 2006; 17:1177–1186.
81.
MannoCS, ChewAJ, HutchisonS, et al.AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood, 2003; 101:2963–2972.
